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Although the existence of an immune response against tumor cells is well documented,
the fact that tumors take off in cancer patients indicates that neoplastic cells can circum-
vent this response. Over the years many investigators have described strategies to rescue
the anti-tumor immune response with the aim of creating specific and long-lasting pro-
tection against the disease. When exported to human clinical settings, these strategies
have revealed in most cases a very limited, if any, positive outcome. We believe that the
failure is mostly due to the inadequate triggering of the CD4+ T helper (TH) cell arm of
the adaptive immunity, asTH cells are necessary to trigger all the immune effector mecha-
nisms required to eliminate tumor cells. In this review, we focus on novel strategies that by
stimulating MHC class II-restricted activation ofTH cells generate a specific and persistent
adaptive immunity against the tumor. This point is of critical importance for both preven-
tive and therapeutic anti-tumor vaccination protocols, because adaptive immunity with its
capacity to produce specific, long-lasting protection and memory responses is indeed the
final goal of vaccination. We will discuss data from our as well as other laboratories which
strongly suggest that triggering a specific and persistent anti-tumor CD4+TH cell response
stably modify not only the tumor microenvironment but also tumor-dependent extratumor
microenvironments by eliminating and/or reducing the blood-derived tumor infiltrating cells
that may have a pro-tumor growth function such as regulatory CD4+/CD25+ T cells and
myeloid-derived-suppressor cells. Within this frame, therefore, we believe that the estab-
lishment of a pro-tumor environment is not the cause but simply the consequence of
the tumor strategy to primarily counteract components of the adaptive cellular immunity,
particularly TH lymphocytes.
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INTRODUCTION
The onset, expansion, persistence, and spreading of tumors are
under the control of a complex series of events that encompass
both intrinsic modifications of cancer cells, such as genetic muta-
tions in proto-oncogenes and in tumor suppressor genes, and
alteration of the apoptotic process, which cumulatively impact
on the homeostasis of the cell cycle, as well as extrinsic mech-
anisms related to the capacity of the host to counteract tumor
growth (1). As far as host mechanisms counteracting the tumor,
certainly the immune system plays a major role. The key functions
of the immune system consist in the capacity to recognize and
fight “foreign aggressors” (the non-self), while sparing self con-
stituents (tolerance), and in conserving specific memory of this
event, should foreign aggressors be encountered again (2). Under
this view, the genetic modifications affecting tumor cells may lead
to the generation of structurally altered or abundantly synthesized
proteins that may be seen by the immune system as new antigens
or “non-self” products against which the system has not learned
to be tolerant during ontogenesis (3). Both innate and adaptive
immunity have been shown to participate to this response (4).
Nevertheless, the fact that the tumor process takes off in cancer
patients demonstrates that the recognition of cancer cells and/or
the equilibrium between tumor growth and anti-tumor immune
response can be altered, favoring the progression of the malig-
nancy (5, 6). Tumor development and response of the immune
system have long been considered opposing actions in the cancer
history. However, accumulating data strongly indicate that the two
events can synergize, particularly for the tumor prosperity. Tumor
cells may, for example, produce mediators that not only coun-
teract the possible protective anti-tumor action of the immune
system but also induce immune cells to produce factors or to
polarize their functional phenotype in favor of the growth and
the expansion of the tumor, thus completely deviating the goal
of the immune response (7). Moreover, tumor infiltrating leuko-
cytes, including macrophages (7, 8), regulatory T cells (Tregs) with
CD4+/CD25+phenotype and suppressive function on helper and
effector T cells (9), as well as a heterogeneous group of simi-
larly acting myeloid-derived suppressor cells (MDSCs) (10), can
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cooperate in antagonizing the protective immune response while
favoring tumor growth. All together, these observations have cre-
ated the diffuse belief that a pro-tumor polarization of the innate
and adaptive immunity is a sort of inevitable event in the life his-
tory of the tumor and a major cause for cancer cells to survive,
replicate, and spread.
We have recently discussed a different interpretation of this
key issue (11, 12). Indeed, the establishment of a pro-tumor envi-
ronment may not be the cause but the consequence of the initial
inability of the immune system to be efficiently triggered against
the tumor. Within this frame, one crucial aspect is the initial
recognition of tumor-associated antigens (TAAs) by the adaptive
immune system. Two fundamental events must take place in order
to initiate the adaptive immune response: (a) antigen processing of
complex antigens and presentation of appropriate peptides within
the context of MHC class II molecules; (b) recognition of MHC
class II-bound peptides displayed on the cell surface by MHC class
II-restricted CD4+ T cells, designated T helper (TH) cells (13).
TH cells are fundamental for optimal induction of both humoral
and cellular effector mechanisms (14), particularly for the matu-
ration of MHC class I-restricted CD8+ naïve T cells, their clonal
expansions, and acquisition of cytolytic function (15). The latter
function is of relevance in the context of anti-tumor immunity
since CD8+ cytolytic T cells (CTLs) are believed to be the major
lymphocyte effectors against cancer cells (16).
Initial priming and triggering of naïve antigen-specific TH cells
are believed to be mediated by specialized MHC class II-positive
cells, particularly dendritic cells (DC), which engulf exogenous
antigenic material (pathogens, pathogen debris, cell debris), digest
it in appropriate endosomal compartments, degrade the build-
ing blocks of life material, that is the proteins, into peptides, and
allow the binding of antigenic peptides to MHC class II mole-
cules. The MHC-II–peptide complexes can thus migrate to the
cell surface and be displayed for TH cell scrutiny. This general
mechanism would imply that endogenously synthesized protein,
as tumor antigens are, may not be presented within the context
of MHC class II unless they are captured as secreted products
or as cell debris-associated components by DC surrounding or
infiltrating tumor masses. However, previous elegant studies have
shown that endogenous proteins could access the MHC class II
pathway of antigen presentation (17, 18) and peptides of these
proteins could be recognized and serve as immunogens for TH
cell triggering (19, 20).
The majority of tumors, particularly carcinomas, usually do
not express MHC class II molecules that are instead expressed
by professional antigen presenting cells (APCs) such as DC,
macrophages, and B cells (13). Furthermore, although in some cir-
cumstances tumor cells may express MHC class II molecules, these
cells are believed to act at most as “peptide antigen presenters” to
antigen-specific primed TH cells but not as “antigen processors
and presenters” for naïve TH cell priming. This is only partially
true, since we have demonstrated that, at least in vitro, human
or murine engineered-tumor cells, stably expressing MHC class II
molecules, can process protein antigens and present relevant pep-
tides to MHC-II-restricted antigen-specific T cell clones (21, 22).
These results have shown that the intracellular machinery respon-
sible for digesting and exposing MHC-II–peptide complexes on
the cell surface for TH cell recognition may work properly also in
cells which are not classical APC, and notably in MHC-II-positive
tumor cells.
Within this frame, the fact that most tumor cells do not express
MHC class II molecules prevents even the possibility that these
cells may act as potential APCs for their TAAs and by consequence
that they may trigger tumor-specific TH cells.
In this review, we will discuss data from our as well as from
other laboratories that strongly suggest how the initial insurgence
of the tumor process and the efficient response of the adaptive
immune system to the tumor are strongly conditioned by the fact
that tumor cells may or may not express MHC class II molecules
in the appropriate “physiological” condition, and by the fact that
insufficient amount of tumor antigens is offered in a MHC class
II-restricted fashion to TH cells.
These two events dramatically influence the formation and
the functional role of the tumor microenvironment, conceived
not only as tumor tissue but also as tumor-dependent microen-
vironments at distant sites, particularly in lymphoid tissues of
tumor-bearing hosts. We will stress the concept that the genera-
tion of a pro-tumor microenvironment is not the cause but the
consequence of the failure of the adaptive immune system to rec-
ognize MHC-II–tumor peptide complexes by tumor-specific TH
cells.
INDUCTION OF CANONICAL MHC CLASS II EXPRESSION IN
TUMOR CELLS MAY TRIGGER A PROTECTIVE ANTI-TUMOR
IMMUNE RESPONSE IN VIVO
The idea to promote anti-tumor adaptive immune responses
in vivo by providing adequate antigen availability (AAA), that
means not only sufficient amount of antigen but also access of
this antigen to MHC-II binding for optimal triggering of TH cells
(12), has been approached from different standpoints. For exam-
ple, irradiated or genetically modified tumor cells have been used
even in clinical trials with the goal to provide host APC with suffi-
cient amount of TAA or to generate, within the tissue injected with
tumor cells, a suitable milieu for optimal APC uptake and presen-
tation of tumor antigens by APC via their MHC class II molecules
(23). DC loaded with TAAs have been also used with the aim of
providing a direct source of ready-to-use MHC-II–tumor peptide
complexes for optimal priming and triggering of TH cells (24,
25) and recent clinical results in melanoma patients give further
hope in improving clinical responses by this approach (26). Several
groups, including ours, have instead investigated the possibility to
render tumor cells themselves MHC class II-positive and thus used
them as potential surrogate APC for triggering tumor-specific TH
cells (27–29). Within this frame, two distinct approaches have been
described. The group of Ostrand-Rosenberg induced MHC class
II expression in tumor cells by transfecting isolated MHC alpha-
and beta chain-encoding genes (28, 30), whereas our group has
privileged the transfection of tumor cells with the MHC class II
transcriptional activator (CIITA), which is the physiological reg-
ulator of expression of all MHC class II genes (31–33). CIITA
regulates also the expression of other fundamental genes necessary
for MHC-II transport to endosomal compartments and loading
of peptides, including the invariant chain (In chain) and DM (34–
37). In the first approach, by expressing only isolated MHC class
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II molecules without expression of In chain, both the district
of interaction and the quality of interacting peptides, including
tumor-associated peptides, are totally different as compared to the
site and the peptides interacting with physiologically expressed
MHC class II molecules. The rationale underlying this approach
was to allow peptides from TAAs, which are endogenous proteins,
to associate with MHC class II molecules in the ER, similarly to
what happens for MHC class I-peptide binding, and thus allow
better recognition of putative tumor antigens by MHC class II-
restricted TH cells. However, although with the SaI sarcoma model
(mostly used by the Ostrand-Rosenberg group) protective immu-
nity could be generated in vivo by vaccinating mice with MHC-II
(alpha-beta)-transfected cells, the cellular correlates of protection
remained not completely clarified, because no other tumor mod-
els were studied intensively. In the SaI tumor model, it has been
suggested that tumor cells may not act directly as surrogate APCs
but as donors of peptide–MHC class II complexes for professional
APC, such as DC, that in turn stimulate TH cells (30). However,
it must be kept in mind that in the absence of In chain hardly
any MHC class II molecules are in a stable peptide-loaded form.
Cells from In chain knock-out mice show a dramatic reduction
in cell surface MHC class II molecules, resulting from both defec-
tive association of class II alpha- and beta-chains and markedly
decreased post-Golgi transport. The few class II alpha/beta het-
erodimers reaching the cell surface behave as empty molecules or
as molecules occupied by an easily displaced peptide, and display
a distinct structure. Moreover spleen cells from these mice are
defective in their ability to present intact protein antigens (36, 38).
Our approach based on CIITA-mediated expression of MHC
class II molecules as well as upregulation of In chain, seemed to us
more prone to mimic the physiological condition by which TAA-
derived peptides may be charged onto MHC-II in a more stable
way and exposed to the cell surface for TH cell scrutiny. Indeed,
it was possible to show that CIITA-transduced tumor cells of at
least four distinct histological origin can be efficiently rejected or
strongly prevented in their growth when injected into immuno-
competent syngeneic mice (22, 27, 39), demonstrating the general
applicability of our model system. Furthermore, it was shown that
mice vaccinated with CIITA-transfected tumor cells develop an
anamnestic response not only against the CIITA-expressing tumor
but also, most importantly, against the CIITA-negative parental
tumor cells leading to a very efficient rejection of the parental
tumor (22, 27, 39). CIITA-dependent MHC class II expression in
tumor cells was instrumental to trigger the anamnestic protective
immune response against the parental tumor, as also demon-
strated by vaccination experiments with non-replicating CIITA-
transfected tumor cells (40). The search for cellular correlates
of protection highlighted three fundamental points. Firstly, long-
lasting immunity was generated in CIITA-vaccinated mice since
these animals were able to reject parental tumors after 6 months
from initial vaccination. Second, rejection and/or reduced tumor
growth were mediated by tumor-specific CD4+ TH and CD8+
CTL, because ablation of these subpopulations in vivo by injec-
tion of specific anti-CD4 or anti-CD8, but not by anti-B cell or
anti-NK cell monoclonal antibodies, prevented the acquisition of
protective immunity after injection of CIITA-expressing tumor
cells. Third, and of particular relevance, transfer of purified CD4+
T cells from vaccinated mice into naïve recipients was sufficient to
confer protection against parental tumors (22, 27, 39, 40).
These results demonstrated that expression of CIITA-mediated
MHC class II molecules in tumor cells was instrumental in trig-
gering a protective adaptive immune response in immunocompe-
tent mice. One possible conclusion from these findings was that
tumor cells expressing CIITA-dependent MHC-II molecules could
serve themselves as APC of their own TAA for initial triggering
and priming of tumor-specific TH cells. Alternatively, preformed
MHC-II–TAA peptide complexes derived from CIITA-transfected
tumor cells could be shed from the cells, captured by professional
APC and used by these cells to reach the AAA necessary to trigger
an efficient priming of tumor-specific CD4+ TH cells.
CHARACTERIZATION OF THE TUMOR AND LYMPOID ORGANS
MICROENVIRONMENT IN CIITA-TUMOR VACCINATED MICE
AND IN PARENTAL TUMOR-BEARING MICE
To further investigate the crucial issue of the possible direct APC
function of CIITA-transfected tumor cells, a series of experiments
were undertaken in our laboratory focusing first on the histological
characterization of the tumor microenvironment in CIITA-tumor
and in parental tumor-injected mice (22). While tumors derived by
injecting parental, MHC-II-negative cells showed very poor, if any,
infiltration of lymphocytes and scarce presence of macrophage and
neutrophils in several tumor models, CIITA-transfected MHC-II
positive tumors were rapidly and firstly infiltrated by CD4+ T
cells, followed by CD8+ T cells, and later by DC, macrophage,
and neutrophils. Already in the early phase of CD4+ and CD8+
T cell infiltration, extensive areas of tumor cell necrosis sur-
rounded by the above T cells and progressively infiltrated by large
numbers of neutrophils could be observed. Indeed, the histolog-
ical picture observed in the tumor microenvironment generated
by CIITA-transfected tumor cells was the classical picture of an
inflammatory lesion. Most importantly, parental tumor rechal-
lenge of CIITA-vaccinated mice showed a histological aspect of the
tumor tissue virtually superimposable to the one observed in naïve
mice injected with CIITA-tumor cells. Indeed, in CIITA-tumor
vaccinated and parental tumor challenged mice, the lymphocyte
infiltration and the tumor necrotic areas were even more massive
than in naïve mice injected with CIITA-tumor cells (39).
This finding, along with the capacity of CIITA-expressing
tumor cells to process and present antigenic peptides to CD4+
T cells in vitro (21, 22), supports the hypothesis that much of
the tumor-specific TH cell triggering takes place in the tumor tis-
sue as consequence of the recognition of MHC-II–TAA peptide
complexes expressed by CIITA-transfected tumor cells.
If confirmed, this will provide further evidence that tumor cells
can act as APC for MHC-II-restricted TH cells in the absence of
DC. This in turn will show that alternative mechanisms of anti-
gen presentation for TH cell priming in vivo can not only occur
but they can occur in milieus other than lymphoid tissues. A fur-
ther, and in our opinion, extremely important conclusion of these
findings is that MHC-II molecules of CIITA-transfected tumor
cells are indeed loaded with the relevant immunogenic tumor-
derived peptides; these peptides might be eluted out and sequenced
to assess the tumor-associated peptidome, a fundamental step
for constructing more promising anti-tumor vaccines aimed at
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optimally stimulating TH cells. Extending the knowledge of the
repertoire of MHC-bound tumor-derived peptides by purifying
and characterizing the tumor-associated peptidome and choosing
the most appropriate cocktail of peptides to prepare anti-tumor
vaccines has been shown recently to be a very promising approach
for the construction of suitable multi-peptide vaccine in human
renal cancer (41).
The increased immunogenicity of the tumor generated by the
CIITA-mediated MHC-II expression and the consequent adequate
tumor antigen availability at the right time and at the right place
affects dramatically the tumor microenvironment, moving the bal-
ance from a pro-tumor to an anti-tumor microenvironment. The
subversion of the tumor microenvironment affected also the num-
ber of Tregs observed in tumor draining lymph nodes. Tregs are
believed to play an important role in down-modulating the func-
tion of CD4+ TH cells in adaptive immunity, and their number
and function were found to increase in tumor-bearing hosts (9). In
human colorectal cancer, very recently, the presence of Tregs and
the consequent reduced response of anti-tumor CD4+ TH cells
has been associated also to the progression of the diseases (42).
Accordingly, we found that parental tumor-bearing mice had a
substantial increase in the number of Tregs in tumor draining
lymph nodes (40), although the relative suppressive capacity of
these cells on TH function in vitro and on tumor growth in vivo
was not increased (43). On the other hand, the number of Tregs
in CIITA-tumor injected and protected mice was found to be
much lower and virtually superimposable to that of naïve mice
(40). Thus, initial optimal triggering of the adaptive immune
response against the tumor prevented the increase of a crucial
cellular component with suppressive function on CD4+ TH cells
and with pro-tumor behavior on tumor microenvironment. Active
investigation is also focused, at present, on the possibility that
CIITA-tumor vaccination may also affect the function and/or the
number of other cells, like MDSC, with suppressive function on
adaptive anti-tumor immunity, particularly in light of recent find-
ings suggesting that MDSC can act as tolerizing cells toward tumor
antigen recognition in specialized sites of the splenic lymphoid
tissue (44).
ANTI-TUMOR IMMUNITY ELICITED AFTER CHEMOTHERAPY,
RADIOTHERAPY, AND CYTOKINE THERAPY: THE CONCEPT OF
THERAPY-INDUCED ANTI-TUMOR VACCINATION
In recent years, it has become apparent that the beneficial
effects of various conventional therapeutic modalities, includ-
ing chemotherapy and radiation therapy, are associated with the
rescue of an immune response against the tumor.
Most chemotherapeutic drugs exert their action through the
induction of apoptosis, a mechanism that has long been inter-
preted as generating tolerogenic signals for the immune system.
This was generally attributed to the scarce or absent inflammation
generated by the apoptotic process and thus by the impossi-
bility to trigger leukocyte migration and lymphocyte activation.
However, after the important work of the Novak and colleagues,
it appeared that drug-induced apoptotic tumor cells behave as
potent “providers” of immunogenic tumor antigens for APC-
dependent cross-stimulation of tumor-specific CTL (45). After
this observation, many studies have confirmed that not only
gemcitabine (the drug initially used by Novak et al.) but also
cyclophosphamide, oxaliplatin, cisplatin, etoposide, topotecan,
paclitaxel, and vinblastine may increase tumor recognition by the
immune system via several mechanism not only related to apopto-
sis induction but also to the capacity of these drugs to upregulate
the expression of tumor antigens and to increase MHC class I
expression on tumor cells, thus favoring recognition and trigger-
ing of tumor-specific CTL (46, 47). Within this frame, it has been
shown that chemotherapy may activate also innate immune effec-
tors such as NK cells (48). The detailed study of the effect of
chemotherapy on the anti-tumor immune response has provided
new information on the complexity of actions and targets that the
treatment brings about. Indeed, chemotherapy may be beneficial
not only because it activates immune effectors but also because
it counteracts negative regulators of anti-tumor immunity in the
tumor microenvironment and at distant sites. In fact, chemother-
apy may reduce the infiltration of Tregs (49–51) and may reduce
the action and/or decrease the number of MDSC (52, 53).
Similarly to chemotherapy, radiotherapy can be associated to
the elicitation of an immune response against the tumor (54).
Radiotherapy very often induces an inflammatory reaction. It
is widely believed that radiation-mediated inflammation pro-
motes tissue necrosis (54, 55) and necrotic tissue may constitute a
major source of tumor antigen for triggering adaptive immune
responses. Indeed, radiation can induce antigen release in the
tumor microenvironment, consequent activation of APCs and
triggering of CTL responses (56, 57). Interestingly, radiotherapy
may also influence the activation of tumor-associated DC, dis-
closing the possibility that potentially tolerized DC may re-acquire
strong tumor antigen APC function for immune lymphocyte effec-
tors (58) Moreover, radiation can increase the expression of tumor
antigens (59) and the cell surface expression of MHC class I mol-
ecules by various modalities. Together, these events increase the
potential to present TAA peptides to CTL (60–62). In recent years,
it has become apparent that radiation can also induce apopto-
sis and apoptotic cell death can efficiently support stimulation of
adaptive immunity (63, 64) in a similar way to the observed effect
of chemotherapy.
Not only classical chemotherapy and radiotherapy may induce
triggering of the adaptive immunity, biological therapies such
as the ones that tag the tumor tissue with certain anti-tumor
cytokines may also be responsible of a strong anti-tumor immu-
nity that in certain cases is indeed the mechanism through which
the therapy generates tumor cure and permanent tumor clear-
ance (11, 12, 40, 65). Together with the group of Luciano Zardi
and Laura Borsi, we have investigated the role of TNF-alpha and
Il-2 cytokines conjugated with an scFv antibody (L19) specific
for the extra domain B of fibronectin, selectively expressed in
the neovasculature (66). Injection of L19-mouse TNFα conju-
gate (L19mTNFα) induces a dramatic cell death of established
tumors in several murine tumor models including the WEHI-164
fibrosarcoma, C51 colon carcinoma (67), and N2A neuroblas-
toma (65), because it allows therapeutically active doses of TNFα
to be reached at the tumor site in which the cytokine increases
intravasal coagulation and trombosis around the tumor, further
favoring tumor necrosis. In this approach of targeted tumor ther-
apy, three observations lead us to envisage a crucial participation
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FIGURE 1 |The key actions for establishing a protective anti-tumor
immunity against cancer. The immune response against cancer is put on
break by several mechanisms among which tumor antigen availability and
stimulation of MHC class II-restricted CD4+TH cells are key features
(upper part of the Figure). Insufficient tumor antigen availability and/or
insufficient MHC-II–tumor peptide complexes (cumulatively defined as
adequate antigen availability or AAA) lead to insufficient stimulation of TH
cells. This results in lack of immune effector responses which may favor
the establishment of immune suppressor mechanism on anti-tumor
responses, such as polarization of TH responses toward a TH2 phenotype,
activation and increase number of regulatory T cells (Treg) and
myeloid-derived-suppressor cells (MDSC), which cumulatively create a
pro-tumor polarization of the tumor microenvironment. Presence of AAA
(lower part of the Figure) generated, for example, by MHC class II
expression in tumor cells or by therapy-induced immunogenic cell death
efficiently triggers tumor specific TH cells and this is instrumental to both
activate immune effector mechanisms such as CTL and repress and/or
prevent suppressor mechanisms on protective immunity. This results in
the generation of an anti-tumor microenvironment and in a strong adaptive
immune response against the tumor.
of the adaptive immune system to the tumor cure: (a) the high rate
of complete and long-lasting tumor eradication, (b) the fact that
tumor-bearing immunodeficient SCID mice were partially resis-
tant to the L19mTNFα treatment even when combined with the
cytostatic drug melphalan, and (c) most importantly, the fact that
cured mice were resistant to challenge with parental tumor (67).
Indeed, immunological studies demonstrated that cured mice
developed both anti-tumor CD8+ and CD4+ T cell immunity.
Importantly, adoptive cell transfer of CD4+ T cells from cured
mice into naïve recipients was sufficient to protect the animals
from tumor take (43, 65, 67). These studies lead us to formulate the
concept of therapy-induced anti-tumor vaccination because defin-
itive cure of the tumor was achieved after elicitation of a potent
adaptive immune response and the treatment was instrumental in
reaching protective immunity. The study of the tumor microen-
vironment in this tumor model was of particular relevance for
refining the concept of therapy-induced anti-tumor vaccination.
In fact the tumor microenvironment after L19mTNFα alone or in
combination with L19mIL-2 showed a marked cellular remodeling
with respect to the one observed before therapy. Extensive areas of
necrosis infiltrated by granulocytes and macrophages and partic-
ularly by CD4+ and CD8+ T cells were observed. The generation
of an abundant tumor necrotic material, together with the known
effect of TNFα in recruiting DC in inflammatory sites (68) could
be a crucial element to generate AAA for fueling professional APC,
thus reaching optimal saturation of MHC class II molecule-tumor
peptide complexes on DC. These APC could then stimulate spe-
cific anti-tumor TH cells and effector CTL, leading to the complete
rejection of the tumor and to the establishment of a critical reser-
voir of memory effector cells responsible for the accelerated rejec-
tion of the tumor upon challenge. Again, the therapeutic approach
was instrumental in creating the conditions for a protective anti-
tumor adaptive immune response responsible of the tumor elimi-
nation. The immune-related modification of the tumor microen-
vironment following therapeutic treatment was also strongly
appreciated in the tumor draining lymphonodes and in the spleen.
The predominant presence of CD4+ TH2-type cells observed in
tumor-bearing hosts before therapy was reconverted in a predom-
inant, although not exclusive, presence of TH1-type cells (43, 65).
A further element of remodeling of the tumor microenvironment
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consisted in the modification of the number, but not the function,
of regulatory Tregs with suppressive characteristics on CD4+ TH
cells (43). Thus, similarly to the preventive vaccination approach
with CIITA-expressing tumor cells, the protective anti-tumor
immune response generated by the treatment with L19mTNFα
was associated to a rapid appearance and conversion toward a TH1
immune phenotype. This preliminary in vivo experimental inves-
tigation has paved the way to initiate clinical trials with L19mTNFα
and melphalan in patients with selected tumors (69, 70).
A HIERARCHIC MODEL FOR THE PROTECTIVE ANTI-TUMOR
IMMUNITY
We have seen how either preventive or therapeutic anti-tumor
modalities may generate an anti-tumor immune response that
in many cases strongly contribute to the modification of the
tumor microenvironment and to the eradication of the neoplastic
lesion. These results give strong support to the idea that a correct
stimulation of the immune system,particularly of the adaptive arm
of it, constitutes a primary strategy to be pursued for combating
and defeating cancer (see Figure 1). With the exception of preven-
tive vaccination approaches whose final goal is indeed to primarily
trigger the adaptive immune system and generate long-lasting
immunity against cancer, other classical therapeutic approaches
have unveiled the participation of different components of the
immune system to a possible successful outcome upon therapy.
Recent excellent reviews have summarized the mechanisms and
the distinct components of the immune systems that are involved
in such therapeutic approaches (46, 54, 71). However, the many
possible players that the immune system may use for either trig-
gering a positive response or counteracting a suppressive response
against the tumor are not, in our opinion,equally important for the
elicitation of a protective immune response against cancer. Based
on our experience and on the results of many groups described in
this review, we believe that a crucial and hierarchically predomi-
nant step is constituted by the efficacy of MHC class II-restricted
tumor antigen presentation to CD4+ TH cells (see Figure 2). We
have defined this step as AAA to indicate the optimal tumor anti-
gen dose and related antigen processing and MHC-II-restricted
presentation necessary to efficiently trigger tumor-specific TH
cells (12). We have shown that AAA can be obtained in several
ways either by inducing MHC class II expression in tumor cells by
transfection with the AIR-1 gene-encoded MHC CIITA, thus pro-
viding functionally sufficient MHC-II–tumor peptide complexes
for TH cell scrutiny, or by increasing the availability of tumor anti-
gens by specific treatment of established tumors with L19mTNFα.
The fundamental finding of both approaches was the elicitation
of long-lived anti-tumor specific TH cells capable to eradicate the
tumor and to protect the host against further tumor challenge. The
primary importance of AAA in the hierarchic scale of anti-tumor
immunity stems also from the fact that the correct triggering of
TH cells was sufficient to unleash the chain of events leading to
a strong effector CTL response and to the abrogation or, at least,
the attenuation of suppressor mechanisms operating on the anti-
tumor immune response (Figure 1). Moreover, and importantly,
the optimal initiation of the adaptive immune response dictated by
AAA was sufficient to reorient the tumor microenvironment from
a pro-tumor to an anti-tumor microenvironment. Thus, in a sort
FIGURE 2 | Proposed hierarchic position of components of the immune
system involved in the productive response against cancer. By
similarity with the pictorial representation of the “Cortical Homunculus” of
W. Penfield, a hypothetical “Immunological Homunculus” is depicted
identifying specific components of the immune system as the hierarchically
most important actors against the tumor. These are, in primis, the tumor
antigen presenting function exerted, for example, by dendritic cells or by
tumor cells expressing MHC class II molecules, and the MHC class
II-restricted CD4+T helper cells. Other important components are defined
as effector cells, innate immunity components, and soluble mediators.
of re-edition of the immunological homunculus theory originally
proposed by Cohen to explain autoimmunity (72), we propose that
most of the protective control exerted by the adaptive immune sys-
tem on cancer derives from AAA (APC and MHC-II, the hand in
Figure 2) and consequent activation of tumor specific TH cells
(the face in Figure 2).
By similarity, we believe that classical anti-tumor chemothera-
peutic or radiotherapeutic approaches that generate or increase an
underlying anti-tumor adaptive immune response are most suc-
cessful when they can generate AAA and indeed many examples
supporting this concept have been described (56, 60, 61, 73).
CONCLUDING REMARKS AND PERSPECTIVE FOR
VACCINATION AGAINST HUMAN TUMORS
A large number of studies both in animal experimental tumor
models and in human tumor-bearing hosts have strongly
suggested that anti-tumor immunity can be triggered and/or
implemented by several preventive and therapeutical modalities.
Can we translate this information to provide in the very near future
better anti-tumor treatments and, hopefully, more reliable anti-
tumor cure? Spontaneous or experimentally induced HLA class II
expression by exogenously transferred CIITA in tumor cells may
be instrumental to purify and sequence more immunogenically
relevant HLA class II-bound TAA peptides. In conjunction with
similarly derived HLA class I-restricted TAA peptides, they will
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be the basis for the construction of a multi-peptide, multi-epitope
vaccine that can target both CD4+TH and CD8+CTL anti-tumor
responses.
In relation to chemotherapy, radiotherapy, and cytokine-
mediated therapy and their effects on anti-tumor immunity, we
believe it will be of particular relevance to select new drugs,
to apply radiotherapeutic modalities, and to construct cytokine-
based compounds, respectively, that may offer the best effects in
stimulating AAA and consequent triggering of anti-tumor specific
TH cells. This, in turn, will set the ground for the generation of
what we have defined as therapy-induced anti-tumor vaccination.
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